HIV gp120 H375 Is Unique to HIV-1 Subtype CRF01_AE and Confers Strong Resistance to the Entry Inhibitor BMS-599793, a Candidate Microbicide Drug

ABSTRACT BMS-599793 is a small molecule entry inhibitor that binds to human immunodeficiency virus type 1 (HIV-1) gp120, resulting in the inhibition of CD4-dependent entry into cells. Since BMS-599793 is currently considered a candidate microbicide drug, we evaluated its efficacy against a number of primary patient HIV isolates from different subtypes and circulating recombinant forms (CRFs) and showed that activity varied between ∼3 ρM and 7 μM at 50% effective concentrations (EC50s). Interestingly, CRF01_AE HIV-1 isolates consistently demonstrated natural resistance against this compound. Genotypic analysis of >1,600 sequences (Los Alamos HIV sequence database) indicated that a single amino acid polymorphism in Env, H375, may account for the observed BMS-599793 resistance in CRF01_AE HIV-1. Results of site-directed mutagenesis experiments confirmed this hypothesis, and in silico drug docking simulations identified a drug resistance mechanism at the molecular level. In addition, CRF01_AE viruses were shown to be resistant to multiple broadly neutralizing monoclonal antibodies. Thus, our results not only provide insight into how Env polymorphisms may contribute to entry inhibitor resistance but also may help to elucidate how HIV can evade some broadly neutralizing antibodies. Furthermore, the high frequency of H375 in CRF01_AE HIV-1, and its apparent nonoccurrence in other subtypes, could serve as a means for rapid identification of CRF01_AE infections.

[1]  C. Charpentier,et al.  Prevalence of subtype-related polymorphisms associated with in vitro resistance to attachment inhibitor BMS-626529 in HIV-1 'non-B'-infected patients. , 2012, The Journal of antimicrobial chemotherapy.

[2]  N. Meanwell,et al.  In Vitro Antiviral Characteristics of HIV-1 Attachment Inhibitor BMS-626529, the Active Component of the Prodrug BMS-663068 , 2012, Antimicrobial Agents and Chemotherapy.

[3]  K. Ikuta,et al.  Molecular Evolution of HIV-1 CRF01_AE Env in Thai Patients , 2011, PloS one.

[4]  Mario Roederer,et al.  Focused Evolution of HIV-1 Neutralizing Antibodies Revealed by Structures and Deep Sequencing , 2011, Science.

[5]  Yundong Wu,et al.  Understanding the binding mode and function of BMS‐488043 against HIV‐1 viral entry , 2011, Proteins.

[6]  P. Ghys,et al.  Global trends in molecular epidemiology of HIV-1 during 2000–2007 , 2011, AIDS.

[7]  Oliver Laeyendecker,et al.  Increased Rate of CD4+ T-Cell Decline and Faster Time to Antiretroviral Therapy in HIV-1 Subtype CRF01_AE Infected Seroconverters in Singapore , 2011, PloS one.

[8]  P. Harrigan,et al.  Genotypic inference of HIV-1 tropism using population-based sequencing of V3. , 2010, Journal of visualized experiments : JoVE.

[9]  Stephen R Comeau,et al.  Achieving reliability and high accuracy in automated protein docking: Cluspro, PIPER, SDU, and stability analysis in CAPRI rounds 13–19 , 2010, Proteins.

[10]  R. Pantophlet.  Antibody epitope exposure and neutralization of HIV-1. , 2010, Current pharmaceutical design.

[11]  Rajesh P. Ringe,et al.  Variations in autologous neutralization and CD4 dependence of b12 resistant HIV-1 clade C env clones obtained at different time points from antiretroviral naïve Indian patients with recent infection , 2010, Retrovirology.

[12]  J. Meulen,et al.  Pushing the envelope on HIV-1 neutralization , 2010, Nature Biotechnology.

[13]  Mario Roederer,et al.  Rational Design of Envelope Identifies Broadly Neutralizing Human Monoclonal Antibodies to HIV-1 , 2010, Science.

[14]  A. Bonvin,et al.  The HADDOCK web server for data-driven biomolecular docking , 2010, Nature Protocols.

[15]  K. White,et al.  Visualizing the molecular interactions of a nucleotide analog, GS-9148, with HIV-1 reverse transcriptase-DNA complex. , 2010, Journal of molecular biology.

[16]  Yundong Wu,et al.  Understanding of the bridging sheet formation of HIV-1 glycoprotein gp120. , 2009, The journal of physical chemistry. B.

[17]  M. Wainberg,et al.  Signature nucleotide polymorphisms at positions 64 and 65 in reverse transcriptase favor the selection of the K65R resistance mutation in HIV-1 subtype C. , 2009, The Journal of infectious diseases.

[18]  F. Maurel,et al.  Docking and 3D-QSAR studies of BMS-806 analogs as HIV-1 gp120 entry inhibitors. , 2009, European journal of medicinal chemistry.

[19]  Lynn Morris,et al.  Limited Neutralizing Antibody Specificities Drive Neutralization Escape in Early HIV-1 Subtype C Infection , 2009, PLoS pathogens.

[20]  Arthur J. Olson,et al.  AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading , 2009, J. Comput. Chem..

[21]  S Gnanakaran,et al.  Highly complex neutralization determinants on a monophyletic lineage of newly transmitted subtype C HIV-1 Env clones from India. , 2009, Virology.

[22]  J. Sodroski,et al.  Identification of a Human Immunodeficiency Virus Type 1 Envelope Glycoprotein Variant Resistant to Cold Inactivation , 2009, Journal of Virology.

[23]  C. Simmerling,et al.  Drug pressure selected mutations in HIV-1 protease alter flap conformations. , 2009, Journal of the American Chemical Society.

[24]  A. Nadas,et al.  Neutralization patterns and evolution of sequential HIV type 1 envelope sequences in HIV type 1 subtype B-infected drug-naive individuals. , 2008, AIDS research and human retroviruses.

[25]  Yasuhiro Suzuki,et al.  Characterization of a CD4-independent clinical HIV-1 that can efficiently infect human hepatocytes through chemokine (C-X-C motif) receptor 4 , 2008, AIDS.

[26]  Sebastian Bonhoeffer,et al.  Viral Dynamics and In Vivo Fitness of HIV-1 in the Presence and Absence of Enfuvirtide , 2008, Journal of acquired immune deficiency syndromes.

[27]  G. Sapiro,et al.  Molecular architecture of native HIV-1 gp120 trimers , 2008, Nature.

[28]  Hui Li,et al.  Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection , 2008, Proceedings of the National Academy of Sciences.

[29]  Stephen R Comeau,et al.  ClusPro: Performance in CAPRI rounds 6–11 and the new server , 2007, Proteins.

[30]  Alexandre M J J Bonvin,et al.  HADDOCK versus HADDOCK: New features and performance of HADDOCK2.0 on the CAPRI targets , 2007, Proteins.

[31]  D. Burton,et al.  HIV-1 neutralization: mechanisms and relevance to vaccine design. , 2007, Current HIV research.

[32]  A. Pinter.  Roles of HIV-1 Env variable regions in viral neutralization and vaccine development. , 2007, Current HIV research.

[33]  N. Haigwood,et al.  Mutations in Envelope gp120 Can Impact Proteolytic Processing of the gp160 Precursor and Thereby Affect Neutralization Sensitivity of Human Immunodeficiency Virus Type 1 Pseudoviruses , 2007, Journal of Virology.

[34]  D. Grasela,et al.  Quantitative determination of BMS-378806 in human plasma and urine by high-performance liquid chromatography/tandem mass spectrometry. , 2007, Journal of separation science.

[35]  C. Blish,et al.  HIV-1 subtype A envelope variants from early in infection have variable sensitivity to neutralization and to inhibitors of viral entry , 2007, AIDS.

[36]  Peter D. Kwong,et al.  Characterization of Human Immunodeficiency Virus Type 1 Monomeric and Trimeric gp120 Glycoproteins Stabilized in the CD4-Bound State: Antigenicity, Biophysics, and Immunogenicity , 2007, Journal of Virology.

[37]  M. Luftig,et al.  Structural basis for HIV-1 neutralization by a gp41 fusion intermediate–directed antibody , 2006, Nature Structural &Molecular Biology.

[38]  B. Masquelier,et al.  Susceptibility to antiretroviral drugs of CRF01_AE, CRF02_AG, and subtype C viruses from untreated patients of Africa and Asia: comparative genotypic and phenotypic data. , 2006, AIDS research and human retroviruses.

[39]  James E. Robinson,et al.  Envelope Conformational Changes Induced by Human Immunodeficiency Virus Type 1 Attachment Inhibitors Prevent CD4 Binding and Downstream Entry Events , 2006, Journal of Virology.

[40]  E. Poveda,et al.  HIV entry inhibitors: mechanisms of action and resistance pathways. , 2006, The Journal of antimicrobial chemotherapy.

[41]  H. Katinger,et al.  HIV-1 mutants escaping neutralization by the human antibodies 2F5, 2G12, and 4E10: in vitro experiments versus clinical studies , 2005, AIDS.

[42]  Bette Korber,et al.  Structure of a V3-Containing HIV-1 gp120 Core , 2005, Science.

[43]  P. Nara,et al.  HIV-1: the confounding variables of virus neutralization. , 2005, Current drug targets. Infectious disorders.

[44]  L. Morris,et al.  Predicted genotypic resistance to the novel entry inhibitor, BMS-378806, among HIV-1 isolates of subtypes A to G , 2004, AIDS.

[45]  Conrad C. Huang,et al.  UCSF Chimera—A visualization system for exploratory research and analysis , 2004, J. Comput. Chem..

[46]  R. Nussinov,et al.  Characterization of the Conformational State and Flexibility of HIV-1 Glycoprotein gp120 Core Domain* , 2004, Journal of Biological Chemistry.

[47]  J. Sodroski,et al.  Localized Changes in the gp120 Envelope Glycoprotein Confer Resistance to Human Immunodeficiency Virus Entry Inhibitors BMS-806 and #155 , 2004, Journal of Virology.

[48]  J. Nelson,et al.  Isolation of CD4-Independent Primary Human Immunodeficiency Virus Type 1 Isolates That Are Syncytium Inducing and Acutely Cytopathic for CD8+ Lymphocytes , 2004, Journal of Virology.

[49]  Olson Wc,et al.  Resistance to HIV-1 entry inhibitors. , 2003 .

[50]  N. Meanwell,et al.  Biochemical and Genetic Characterizations of a Novel Human Immunodeficiency Virus Type 1 Inhibitor That Blocks gp120-CD4 Interactions , 2003, Journal of Virology.

[51]  Zheng Yang,et al.  A small molecule HIV-1 inhibitor that targets the HIV-1 envelope and inhibits CD4 receptor binding , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[52]  C. Dominguez,et al.  HADDOCK: a protein-protein docking approach based on biochemical or biophysical information. , 2003, Journal of the American Chemical Society.

[53]  Paul W. H. I. Parren,et al.  Fine Mapping of the Interaction of Neutralizing and Nonneutralizing Monoclonal Antibodies with the CD4 Binding Site of Human Immunodeficiency Virus Type 1 gp120 , 2003, Journal of Virology.

[54]  A. Jetzt,et al.  Human Immunodeficiency Virus Type 1 Recombination: Rate, Fidelity, and Putative Hot Spots , 2002, Journal of Virology.

[55]  J. Sodroski,et al.  Mutagenic Stabilization and/or Disruption of a CD4-Bound State Reveals Distinct Conformations of the Human Immunodeficiency Virus Type 1 gp120 Envelope Glycoprotein , 2002, Journal of Virology.

[56]  R. Doms,et al.  Human immunodeficiency virus type 2. , 2002, Journal of General Virology.

[57]  J. Rose,et al.  Role of N-Linked Glycans in a Human Immunodeficiency Virus Envelope Glycoprotein: Effects on Protein Function and the Neutralizing Antibody Response , 2002, Journal of Virology.

[58]  J. Mascola,et al.  Construction and biological characterization of infectious molecular clones of HIV-1 subtypes B and E (CRF01_AE) generated by the polymerase chain reaction. , 2000, Virology.

[59]  Alexandre M. J. J. Bonvin,et al.  The GROMOS96 benchmarks for molecular simulation , 2000 .

[60]  N. Mochizuki,et al.  An infectious DNA clone of HIV type 1 subtype C. , 1999, AIDS research and human retroviruses.

[61]  G. Simmons,et al.  Primary Human Immunodeficiency Virus Type 2 (HIV-2) Isolates Infect CD4-Negative Cells via CCR5 and CXCR4: Comparison with HIV-1 and Simian Immunodeficiency Virus and Relevance to Cell Tropism In Vivo , 1999, Journal of Virology.

[62]  J L Sussman,et al.  Protein Data Bank (PDB): database of three-dimensional structural information of biological macromolecules. , 1998, Acta crystallographica. Section D, Biological crystallography.

[63]  J. Sodroski,et al.  Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody , 1998, Nature.

[64]  B. Chesebro,et al.  Effects of CCR5 and CD4 Cell Surface Concentrations on Infections by Macrophagetropic Isolates of Human Immunodeficiency Virus Type 1 , 1998, Journal of Virology.

[65]  R. Doms,et al.  CD4-independent, CCR5-dependent infection of brain capillary endothelial cells by a neurovirulent simian immunodeficiency virus strain. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[66]  David S. Goodsell,et al.  Distributed automated docking of flexible ligands to proteins: Parallel applications of AutoDock 2.4 , 1996, J. Comput. Aided Mol. Des..

[67]  A. Perelson,et al.  HIV-1 Dynamics in Vivo: Virion Clearance Rate, Infected Cell Life-Span, and Viral Generation Time , 1996, Science.

[68]  L. M. Mansky,et al.  Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase , 1995, Journal of virology.

[69]  A. Perelson,et al.  Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection , 1995, Nature.

[70]  D R Burton,et al.  Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. , 1994, Science.

[71]  C. Barbas,et al.  Recombinant human Fab fragments neutralize human type 1 immunodeficiency virus in vitro. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[72]  D R Burton,et al.  A large array of human monoclonal antibodies to type 1 human immunodeficiency virus from combinatorial libraries of asymptomatic seropositive individuals. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[73]  R. Siliciano,et al.  Genetic variability in HIV-1 gp120 affects interactions with HLA molecules and T cell receptor. , 1990, Journal of immunology.

[74]  Antony S. Dimitrov,et al.  Neutralization of HIV by antibodies. , 2009, Methods in molecular biology.

[75]  M. Sternberg,et al.  Protein structure prediction on the Web: a case study using the Phyre server , 2009, Nature Protocols.

[76]  J. Bhattacharya,et al.  CD4-independent infection of HIV and SIV: implications for envelope conformation and cell tropism in vivo. , 2003, AIDS.

[77]  W. Olson,et al.  Resistance to HIV-1 entry inhibitors. , 2003, Current drug targets. Infectious disorders.

[78]  B. Preston.  Reverse transcriptase fidelity and HIV-1 variation. , 1997, Science.

[79]  J. Moore,et al.  HIV-1 neutralization: the consequences of viral adaptation to growth on transformed T cells. , 1995, AIDS.